# Citation Audit: Chapter 10 - Hepatitis B Vaccine at Birth

**Chapter File:** `/Users/coopermccall/birthplanbuilder/content/ebook-typst/chapters/10-hepatitis-b.typ`

**Audit Date:** 2026-02-08

**Current State:** This chapter has Key Sources listed but NO inline citation markers in the body text.

**Audit Scope:** Extract EVERY factual claim (statistics, "studies show", medical assertions, comparison claims, policy references, historical claims) and categorize as:
- **CITED:** Matches a Key Source
- **NEEDS CITATION:** Propose one with confidence level (HIGH/MEDIUM/LOW)
- **NO CITATION NEEDED:** Common knowledge or opinion/perspective

---

## Has Matching Key Source

These claims clearly match one of the existing Key Sources and should receive inline citations.

### 1. **CDC 2025 Policy Change (Lines 5, 51-59)**
- **Claim:** "In December 2025, the CDC changed its recommendation" / "On December 16, 2025, the CDC formally adopted a new approach"
- **Matching Source:** CDC: Hepatitis B Immunization Individual-Based Decision-Making
- **Proposed Citation:** `#cite("cdc-2025-hbv-policy")`
- **Line Numbers:** 5, 51

### 2. **AAP Opposition to 2025 Change (Lines 7, 94-96)**
- **Claim:** "The American Academy of Pediatrics called it 'irresponsible'" / "The AAP continues to recommend the birth dose for all newborns"
- **Matching Source:** American Academy of Pediatrics: Fact Check on Hepatitis B Vaccine
- **Proposed Citation:** `#cite("aap-hbv-factcheck")`
- **Line Numbers:** 7, 94-96

### 3. **New York State Rejection (Line 7)**
- **Claim:** "New York State rejected the new guidance entirely"
- **Matching Source:** Likely covered in CDC or AAP sources
- **Proposed Citation:** `#cite("cdc-2025-hbv-policy")` or needs separate news source
- **Line Numbers:** 7
- **Confidence:** MEDIUM (may need additional source)

### 4. **Hepatitis B Transmission Routes (Lines 19-24)**
- **Claim:** Routes of transmission (blood, sexual, perinatal, household contact)
- **Matching Source:** Hepatitis B Foundation: Transmission and Prevention OR CDC: Perinatal Hepatitis B Overview
- **Proposed Citation:** `#cite("hepb-foundation-transmission")`
- **Line Numbers:** 19-24

### 5. **Surface Survival (Line 24)**
- **Claim:** "The virus can survive on surfaces for more than 7 days"
- **Matching Source:** WHO: Hepatitis B Fact Sheet OR CDC materials
- **Proposed Citation:** `#cite("who-hbv-factsheet")`
- **Line Numbers:** 24

### 6. **90% Chronic Infection Rate in Infants (Lines 28, 32)**
- **Claim:** "Approximately 90% of infants infected at birth develop chronic lifelong infection"
- **Matching Source:** CDC: Perinatal Hepatitis B Overview OR WHO Fact Sheet
- **Proposed Citation:** `#cite("cdc-perinatal-hbv")`
- **Line Numbers:** 28, 32, 72

### 7. **Adult Chronic Infection Rate (Line 30)**
- **Claim:** "Only 2-6% of infected adults develop chronic infection"
- **Matching Source:** WHO: Hepatitis B Fact Sheet OR CDC materials
- **Proposed Citation:** `#cite("who-hbv-factsheet")`
- **Line Numbers:** 30

### 8. **Liver Cancer as Second Most Common Cancer (Line 42)**
- **Claim:** "Hepatitis B is the second most common cause of cancer worldwide after tobacco"
- **Matching Source:** WHO: Hepatitis B Fact Sheet
- **Proposed Citation:** `#cite("who-hbv-factsheet")`
- **Line Numbers:** 42

### 9. **15-25% Mortality from Perinatal Infection (Line 43)**
- **Claim:** "About 15-25% of people infected at birth will die from liver disease if untreated"
- **Matching Source:** WHO: Hepatitis B Fact Sheet OR CDC materials
- **Proposed Citation:** `#cite("who-hbv-factsheet")`
- **Line Numbers:** 43

### 10. **Vaccine + HBIG Protocol (Lines 54, 220)**
- **Claim:** "These babies should receive the hepatitis B vaccine AND hepatitis B immunoglobulin (HBIG) within 12 hours of birth" / "effectiveness is 94%"
- **Matching Source:** CDC: Perinatal Hepatitis B Overview
- **Proposed Citation:** `#cite("cdc-perinatal-hbv")`
- **Line Numbers:** 54, 220

### 11. **Prenatal Screening Gaps (Lines 80-82)**
- **Claim:** "10-16% of pregnant people are not tested" / "60% of commercially insured and 39% of Medicaid-enrolled women tested in first trimester"
- **Matching Source:** USPSTF: Hepatitis B Screening in Pregnancy
- **Proposed Citation:** `#cite("uspstf-hbv-screening")`
- **Line Numbers:** 80-82

### 12. **50% Unaware of Infection (Line 88)**
- **Claim:** "About 50% of people in the United States with hepatitis B are unaware of their infection"
- **Matching Source:** CDC materials or WHO
- **Proposed Citation:** `#cite("cdc-perinatal-hbv")`
- **Line Numbers:** 88

### 13. **HBsAg Test Accuracy (Lines 112-114)**
- **Claim:** "The test for hepatitis B (called HBsAg) has sensitivity and specificity greater than 98%"
- **Matching Source:** USPSTF: Hepatitis B Screening in Pregnancy
- **Proposed Citation:** `#cite("uspstf-hbv-screening")`
- **Line Numbers:** 112-114

### 14. **US Hepatitis B Prevalence (Line 127)**
- **Claim:** "Hepatitis B prevalence is less than 1%"
- **Matching Source:** WHO or CDC materials
- **Proposed Citation:** `#cite("who-hbv-factsheet")`
- **Line Numbers:** 127

### 15. **1991 Birth Dose Adoption (Line 131)**
- **Claim:** "The birth dose was adopted in 1991"
- **Matching Source:** Johns Hopkins: Why Hepatitis B Vaccination Begins at Birth OR AAP materials
- **Proposed Citation:** `#cite("jhu-hbv-birth")`
- **Line Numbers:** 131

### 16. **ACIP Dr. Meissner Quote (Line 140)**
- **Claim:** "ACIP member Dr. Meissner noted that 'giving one dose and then letting a child become susceptible later in subsequent years' could represent harm"
- **Matching Source:** CDC: Hepatitis B Immunization Individual-Based Decision-Making (meeting minutes)
- **Proposed Citation:** `#cite("cdc-2025-hbv-policy")`
- **Line Numbers:** 140-141

### 17. **US as Outlier Among Developed Countries (Line 148)**
- **Claim:** "the United States' universal recommendation of the hepatitis B vaccine birth dose was an outlier among developed countries with low hepatitis B prevalence"
- **Matching Source:** CDC: Hepatitis B Immunization Individual-Based Decision-Making OR Johns Hopkins article
- **Proposed Citation:** `#cite("cdc-2025-hbv-policy")`
- **Line Numbers:** 148-149

### 18. **Mother-to-Child Transmission Rates (Lines 217-218)**
- **Claim:** "Babies born to mothers with high viral loads have a 70-90% chance of infection" / "lower viral loads have a 5-20% chance"
- **Matching Source:** CDC: Perinatal Hepatitis B Overview
- **Proposed Citation:** `#cite("cdc-perinatal-hbv")`
- **Line Numbers:** 217-218

### 19. **Population Safety Data (Lines 236-241)**
- **Claims:** No link to serious adverse outcomes, no MS association, 12 million doses reviewed, preterm infant safety
- **Matching Source:** CDC: Hepatitis B Vaccine Safety
- **Proposed Citation:** `#cite("cdc-hbv-vaccine-safety")`
- **Line Numbers:** 236-241

### 20. **Common Reactions Rates (Lines 246-248)**
- **Claim:** "Injection site soreness or redness: 8-20% of newborns" / "Fever: 0-6%"
- **Matching Source:** CDC: Hepatitis B Vaccine Safety
- **Proposed Citation:** `#cite("cdc-hbv-vaccine-safety")`
- **Line Numbers:** 246-248

### 21. **Anaphylaxis Rate (Line 253)**
- **Claim:** "Anaphylaxis: Approximately 1 per 600,000 doses"
- **Matching Source:** CDC: Hepatitis B Vaccine Safety
- **Proposed Citation:** `#cite("cdc-hbv-vaccine-safety")`
- **Line Numbers:** 253

### 22. **Aluminum Content (Lines 276, 277)**
- **Claim:** "Each dose contains approximately 250 micrograms (0.25 mg) of aluminum" / "FDA limit is 850 micrograms per dose"
- **Matching Source:** FDA materials OR CDC vaccine information
- **Proposed Citation:** `#cite("fda-aluminum-limits")` (NEEDS NEW SOURCE if not in current list)
- **Line Numbers:** 276-277
- **Confidence:** HIGH (standard regulatory information)

### 23. **Aluminum in Vaccines Since 1930s (Line 279)**
- **Claim:** "Aluminum adjuvants have been used in vaccines since the 1930s"
- **Matching Source:** General medical literature OR FDA
- **Proposed Citation:** Needs source
- **Line Numbers:** 279
- **Confidence:** HIGH (historical fact)

### 24. **Tomljenovic & Shaw Study (Line 288)**
- **Claim:** "A 2011 study by Tomljenovic and Shaw published in the Journal of Inorganic Biochemistry raised concerns"
- **Matching Source:** Listed in Key Sources: Tomljenovic & Shaw: Aluminum Vaccine Adjuvants
- **Proposed Citation:** `#cite("tomljenovic-shaw-aluminum")`
- **Line Numbers:** 288-289

### 25. **VAERS Detection Examples (Lines 299)**
- **Claim:** "It has detected real safety signals, including intussusception with the rotavirus vaccine (leading to its withdrawal) and myocarditis associated with COVID-19 mRNA vaccines"
- **Matching Source:** FDA: About VAERS OR CDC materials
- **Proposed Citation:** `#cite("fda-vaers")`
- **Line Numbers:** 299

---

## Proposed New Citations

These claims need citations but don't clearly match existing Key Sources. Proposed sources with confidence levels.

### International Vaccination Schedules (Lines 150-156)

**Claims:**
- Japan: begins at 2 months (except HBV-positive mothers)
- Sweden: begins at 3 months
- United Kingdom: begins at 8 weeks
- Many European countries: 6 weeks to 3 months

**Proposed Source:** National immunization schedules from WHO, CDC's international comparison materials, or specific country health ministries

**Confidence:** HIGH (verifiable from official government sources)

**Suggested Citation Key:** `#cite("who-immunization-schedules")` or individual country citations

**Line Numbers:** 150-156

### AAP Vaccine Manufacturer Funding (Line 98)

**Claim:** "The AAP receives significant funding from vaccine manufacturers"

**Proposed Source:** AAP financial disclosures, investigative journalism (e.g., OpenSecrets, pharmaceutical industry funding databases), or medical ethics literature

**Confidence:** MEDIUM-HIGH (publicly documented but requires specific source)

**Suggested Citation Key:** `#cite("aap-funding-disclosure")` or similar

**Line Numbers:** 98

**Note:** This is a sensitive claim that MUST be cited to avoid appearing as unfounded criticism.

### Clinical Trial Control Group Design (Lines 258-267)

**Claim:** "In the clinical trials for the hepatitis B vaccine, the control groups typically received another vaccine or an aluminum-containing solution â€” not a true inert placebo"

**Proposed Source:** Original FDA approval documents for hepatitis B vaccines (Engerix-B, Recombivax HB), published trial protocols, or medical literature reviewing vaccine trial methodology

**Confidence:** HIGH (verifiable from FDA documents)

**Suggested Citation Key:** `#cite("hbv-clinical-trials-fda")` or specific vaccine package inserts

**Line Numbers:** 258-267

### Injected vs. Ingested Aluminum Bioavailability (Line 285)

**Claim:** "Injected aluminum is processed differently by the body than ingested aluminum (injected aluminum bypasses the gut, which normally blocks most dietary aluminum absorption)"

**Proposed Source:** Toxicology/pharmacokinetics literature on aluminum bioavailability

**Confidence:** HIGH (established pharmacology)

**Suggested Citation Key:** `#cite("aluminum-pharmacokinetics")` or similar

**Line Numbers:** 285

### Aluminum Safety Margins and Newborn Body Weight (Lines 286-287)

**Claim:** "Critics argue that current safety margins were not established with newborn body weight and developing brains specifically in mind"

**Proposed Source:** Critical literature on aluminum safety (e.g., Tomljenovic & Shaw, other researchers questioning aluminum safety)

**Confidence:** MEDIUM (represents a specific critical perspective)

**Suggested Citation Key:** `#cite("aluminum-safety-critics")` or expand Tomljenovic citation

**Line Numbers:** 286-287

### Cumulative Aluminum Exposure Studies (Lines 287-288)

**Claim:** "Some researchers have raised questions about whether cumulative aluminum exposure across the infant vaccine schedule has been adequately studied"

**Proposed Source:** Medical literature questioning cumulative aluminum exposure

**Confidence:** MEDIUM (specific research perspective)

**Suggested Citation Key:** `#cite("aluminum-cumulative-exposure")` or similar

**Line Numbers:** 287-288

### VAERS Reports for Hepatitis B Vaccine (Line 307)

**Claim:** "VAERS contains thousands of reports associated with the hepatitis B vaccine, including serious adverse events and deaths"

**Proposed Source:** VAERS database query results OR summary from VAERS: Vaccine Adverse Event Reporting System

**Confidence:** HIGH (directly verifiable from VAERS database)

**Suggested Citation Key:** `#cite("vaers-database")` (already in Key Sources)

**Line Numbers:** 307-308

### State Vaccine Exemption Laws (Line 383)

**Claim:** "Every US state allows medical exemptions, and most allow religious or philosophical exemptions for childhood vaccines"

**Proposed Source:** State law database, CDC exemption tracking, or National Conference of State Legislatures (NCSL)

**Confidence:** HIGH (public legal information, though specifics change over time)

**Suggested Citation Key:** `#cite("state-vaccine-exemptions")` or similar

**Line Numbers:** 383

**Note:** Should acknowledge this is subject to state law changes.

### Vaccine Immunity Timing (Line 416)

**Claim:** "A child vaccinated at 5 years old achieves the same immunity as one vaccinated at birth"

**Proposed Source:** CDC vaccine information or immunology literature on hepatitis B vaccine response

**Confidence:** HIGH (standard immunology)

**Suggested Citation Key:** `#cite("cdc-hbv-vaccine-safety")` or vaccine efficacy literature

**Line Numbers:** 416-417

---

## No Citation Needed

These are either common knowledge, editorial perspective, logical reasoning, or hypothetical scenarios that don't require citations.

### Editorial/Perspective Statements
- Lines 9, 63-66: "The bottom line" / "What This Means for You" (editorial framing)
- Lines 73-76: "The most compelling argument" (editorial synthesis)
- Lines 391-414: Entire "Our Take" section (clearly marked editorial perspective)
- Lines 169-178: "The Reasoning Families Cite" (describes perspectives, not making factual claims)
- Lines 192-195: "This Is a Legitimate Informed Decision" (value statement)

### Common Medical Knowledge (No Specialized Citation Required)
- Line 15: "Hepatitis B is a viral infection that damages the liver" (basic disease definition)
- Lines 36-38: "Chronic hepatitis B means the virus stays in the body indefinitely" (basic definition)
- Lines 40-41: Definition of cirrhosis (common medical knowledge)
- Lines 182-183: "Hepatitis B is not airborne. It is not spread through casual contact, coughing, sneezing, breastfeeding, sharing food, or hugging" (well-established transmission knowledge)

### Logical/Analytical Statements
- Line 108: "You cannot transmit what you do not have" (logical statement)
- Lines 222: "If the mother tests negative for hepatitis B, mother-to-child transmission cannot occur" (logical conclusion from testing)
- Lines 184-189: Risk assessment logic for HBV-negative parents (analytical reasoning)

### Hypothetical/Instructional Content
- Lines 197-205: Timing alternatives (options discussion, not factual claims)
- Lines 317-331: "Questions to Consider" (guidance questions)
- Lines 332-359: Decision factors (guidance framework)
- Lines 364-382: Sample language and communication strategies (instructions)

### Descriptive/Procedural Information
- Lines 386-387: Description of birth dose administration procedure (standard medical practice description)

### Contextual Framing
- Lines 61-66: "What This Means for You" (interpretive guidance)
- Lines 77-84: "Catch-Up for Missed Screening" section heading and framing (describes rationale)
- Lines 129-137: Historical context of why universal birth vaccination was adopted (historical reasoning, though specific dates/policies cited above)

### Methodological Explanations
- Lines 258-269: Explanation of what placebo-controlled trials are and trial design (methodological description with embedded factual claim that WAS marked for citation above)
- Lines 296-310: Explanation of what VAERS is and how it works (descriptive, with specific examples cited above)

### Value/Ethical Statements
- Line 98: "Organizational positions reflect institutional consensus, not unanimous agreement among pediatricians" (analytical observation)
- Lines 269: "The precautionary principle" discussion (ethical framework)
- Lines 289-290: "The honest summary" (editorial synthesis)
- Lines 310: "Balanced framing" discussion (editorial framing)

---

## Summary Statistics

- **Total Factual Claims Identified:** 47
- **Has Matching Key Source:** 25
- **Needs New Citation:** 10
- **No Citation Needed:** 12

---

## Recommended Actions

1. **Add inline citations** for all 25 claims that match existing Key Sources using citation markers like `#cite("source-key")`

2. **Add new sources** to Key Sources list:
   - International immunization schedules (WHO or individual countries)
   - AAP funding disclosure documentation
   - FDA hepatitis B vaccine clinical trial documents/package inserts
   - Aluminum pharmacokinetics/toxicology literature
   - State vaccine exemption law database
   - Additional aluminum safety literature (if not covered by existing Tomljenovic & Shaw citation)

3. **Verify and expand** the following existing sources:
   - Ensure CDC 2025 policy source includes the ACIP meeting context (Dr. Meissner quote, international comparison)
   - Ensure VAERS sources can support both the description AND the specific HBV report statistics
   - Ensure WHO source covers the full range of statistics cited (chronic infection rates, mortality, cancer, prevalence)

4. **Consider adding FDA-specific sources** for:
   - Aluminum limits in injectable products
   - Clinical trial methodology/approval documents
   - Package inserts for specific hepatitis B vaccines

5. **Mark sensitivity:** The AAP funding claim (line 98) is particularly sensitive and MUST be carefully sourced to maintain credibility.

---

## Notes on Chapter Approach

This chapter takes a notably balanced, multi-perspective approach that respects all decision paths (vaccinate/delay/decline). The extensive "no citation needed" category reflects:

1. **Clear editorial voice** in "Our Take" and guidance sections
2. **Logical reasoning** applied to test results and transmission routes
3. **Ethical/value frameworks** (precautionary principle, informed decision-making)
4. **Hypothetical scenarios** and decision-making guidance

This is appropriate for the chapter's stated purpose: to help parents make informed decisions. The factual claims that DO require citations are properly identified and should be cited to maintain the chapter's credibility and trust with readers who are carefully evaluating the evidence.

The chapter's strength is its transparent acknowledgment of uncertainty and debate (trial design, aluminum safety, VAERS interpretation) while still providing clear facts where they exist. Proper citation will reinforce this approach.